Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation–associated metastatic renal-cell carcinoma

Samer Alsidawi; Pashtoon Murtaza Kasi

doi:10.1101/mcs.a002220

Figure 2.

An external file that holds a picture, illustration, etc.
Object name is MCS002220Als_F2.jpg

Exceptional response to everolimus seen in a patient with tuberous sclerosis (TSC)-associated RCC. (A) The shrinkage seen in the dominant left renal mass; (B) the reduction in size noted in the para-aortic adenopathy at 3- and 6-mo after starting therapy when compared with baseline. Response is sustained at 2-yr follow-up.